Implementation of HIV Retesting During Pregnancy and Postpartum in Kenya: A Cross-Sectional Study

Monalisa Penumetsa, a Jillian Neary, a Shiza Farid, a Peninah Kithao, b Barbra A. Richardson, c,d Daniel Matemo, b Grace John-Stewart, a,c,e,f John Kinuthia, b,c Alison L. Drake c

Key Findings
- Despite guidelines to conduct maternal HIV retesting during pregnancy, labor/delivery, and postpartum, we found HIV retesting was inconsistently conducted in Kenyan prevention of mother-to-child HIV transmission programs.
- Programmatic retesting was more frequently implemented at 6 weeks and 9 months postpartum than in the pregnancy or delivery.
- HIV incidence was 3-fold higher during pregnancy than postpartum, suggesting fewer infections acquired postpartum in our study.

Key Implications
- Public health practitioners need to consider strategies to prevent missed opportunities to detect and treat incident HIV infections during and after pregnancy.
- Programs focused on the prevention of mother-to-child HIV transmission should measure maternal retesting and document reasons why retesting does not occur to identify service delivery gaps and improve the implementation of programmatic retesting.
- As mother-to-child HIV transmission rates decline over time with effective interventions, it will be increasingly important to monitor the contributions of maternal HIV incidence to new infant infections to achieve elimination of mother-to-child HIV transmission.

ABSTRACT

Introduction: HIV retesting during pregnancy/postpartum can identify incident maternal HIV infection and prevent mother-to-child HIV transmission (MTCT). Guidelines recommend retesting HIV-negative peripartum women, but data on implementation are limited. We conducted a cross-sectional study in Kenya to measure the prevalence of maternal HIV retesting in programs and HIV incidence.

Methods: Programmatic HIV retesting data was abstracted from maternal and child health booklets among women enrolled in a cross-sectional and/or seeking services during pregnancy, delivery, or 9 months postpartum in Kenya between January 2017 and July 2019. Retesting was defined as any HIV test conducted by MTCT programs after the initial antenatal care test or conducted as part of retesting policies at/upon delivery for women not tested during pregnancy. Poisson generalized linear regression was used to identify correlates of programmatic retesting among women enrolled at 9 months postpartum.

Results: Among 5,894 women included in the analysis, 3,124 only had data abstracted and 2,770 were enrolled in a cross-sectional study. Overall prevalence of programmatic HIV retesting was higher at 6 weeks (65%) and 9 months postpartum (72%) than in pregnancy (32%), at delivery (23%) and 6 months postpartum (28%) (P<.001 for all comparisons). HIV incidence was 0.72/100 person-years (PY) (95% confidence interval (CI)= 0.43,1.22) in pregnancy and 0.23/100 PY (95% CI=0.09, 0.62) postpartum (incidence rate ratio: 3.09; 95% CI=0.97, 12.90; P=.02).

Conclusion: Maternal retest coverage was high at 6 weeks and 9 months postpartum but low during pregnancy. Strategies to ensure high retesting coverage and detect women with incident maternal HIV infection are needed.

INTRODUCTION

Globally, 150,000 children became infected with HIV in 2019, the majority of whom acquired HIV through mother-to-child HIV transmission (MTCT).1 Early detection and effective treatment of maternal infection are critical to reducing MTCT, making testing a crucial component of prevention of MTCT (PMTCT) interventions. Integration of HIV testing in antenatal care (ANC) and universal antiretroviral therapy (ART) for pregnant and lactating women living with HIV has been a highly effective strategy to reduce MTCT among women with chronic infection. However, newly acquired HIV infections during and after pregnancy may go undetected and untreated.
HIV incidence is high among pregnant and postpartum women, estimated at 2.1/100 person-years (PY) in studies conducted after 2014 in sub-Saharan Africa. As MTCT risk decreases among women with chronic infection who are effectively treated with ART, the proportion of infant HIV infections attributed to women who acquire HIV infection during pregnancy or postpartum increases. Incident maternal HIV infections are associated with nearly a 10-fold higher risk of MTCT, in the context of universal ART, with MTCT rates ranging from 36%–53%. In the absence of maternal HIV retesting, pregnant and postpartum women who initially test HIV-negative during ANC but acquire HIV later, have undetected infection and miss benefits from PMTCT interventions.

Since 2006, the World Health Organization (WHO) guidelines recommend HIV retesting among HIV-negative pregnant women in the third trimester, at delivery, and/or postpartum. Kenyan guidelines recommend retesting at the third trimester, delivery (if no retesting in pregnancy), and 6 weeks and thereafter every 6 months until the cessation of breastfeeding. Yet, data on implementation of maternal HIV retesting throughout pregnancy and postpartum are sparse. In Zambia, retesting during pregnancy was universal among women who had a second ANC visit, but only 67% of all women were retested due to missed visits. In other studies, in sub-Saharan Africa, HIV retesting during pregnancy ranged from 25%–62%. Despite guidelines recommending postpartum retesting, comprehensive assessments to measure retesting beyond delivery are lacking. Data on coverage of maternal retesting can help policy makers adapt guidelines to optimize retesting and elimination of MTCT (EMTCT). We measured the prevalence of HIV retesting in PMTCT programs during pregnancy, delivery, and postpartum; correlates of retesting through 9 months postpartum; and maternal HIV incidence.

METHODS

Study Design and Participants

Cross-Sectional Study

Women were enrolled in a cross-sectional study at 2 health facilities (Ahero County and Bondo Sub-County Hospitals) in the Nyanza region of Kenya. Women seeking ANC or postnatal/infant immunization care services between January 2017 and July 2019 at these facilities were eligible if they were aged 14 years or older and willing to be tested for HIV and provide written informed consent. Additionally, pregnant women were eligible if their gestational age was 28 weeks or more with a history of an HIV-negative test in pregnancy; postpartum women were eligible if they were 6 weeks, 6 months, or 9 months postpartum and either had a documented HIV-negative test result during pregnancy at least 3 months before study enrollment or were not tested for HIV in ANC.

Programmatic Abstraction Only Study

As programs began implementing maternal HIV retesting more routinely as the standard of care, making it unnecessary to offer retesting as a research procedure, in January 2019, the study protocol was modified to only abstract programmatic maternal and child health (MCH) data (including HIV testing data retrospectively and at the current visit) from women who had an initial HIV-negative test during pregnancy or were postpartum. We refer to this as the programmatic abstraction only study. Women were eligible for participation in the programmatic abstraction only study if they were aged 14 years or older; if women did not know their age they verified they were at least 14. Women were enrolled only at 6 weeks or 9 months postpartum after giving written informed consent. Study staff only offered retesting in the programmatic abstraction only study if clinics were unable to perform retesting on the day of enrollment (i.e., test kit stock-outs or provider unavailable). In addition to Ahero County Hospital and Bondo Sub-County Hospital, women were enrolled at Siaya County Referral Hospital, Rachuonyo Sub-County Hospital, and Riruta Health Center in Nairobi between January 2019 and July 2019. Following implementation of the programmatic abstraction only study, women were enrolled in the cross-sectional study only if they would not have the opportunity for retesting without study staff offering this procedure.

Ethics Approval

The Kenyatta National Hospital/University of Nairobi Ethics and Research Committee and the University of Washington Institutional Review Board approved all study procedures.

Study and Laboratory Procedures

Among women enrolled in the cross-sectional study, a survey was administered by study nurses to collect demographic characteristics, reproductive history, condom use, and male partner characteristics. After survey administration, study staff conducted HIV testing using the Alere
of ANC and postnatal care (PNC) visits were programmatic abstraction only study. The number were examined among women enrolled in the from MCH booklets) and programmatic retesting visits (the only nontesting variables abstracted the cross-sectional study at 9 months postpartum. The relationship between age and number of MCH were identified using all retesting data available up to but excluding the 9 months postpartum visit. The number of ANC visits (n=4) and median number of PNC visits among women enrolled at 9 months postpartum the programmatic abstraction only study. Wilcoxon rank-sum tests were used to compare maternal age and number of MCH visits between women in the programmatic abstraction only and cross-sectional studies. Cofactors for receiving 2 or more retests were identified, which most closely aligns with current Kenyan guidelines11 using Poisson generalized linear models with a log-link function; this approach is appropriate when the prevalence of the outcome is high.17,18 Since programmatic HIV retesting procedures may differ by facility (i.e., personnel or guideline implementation), and we detected differences in retesting by site, site clustering was accounted for in the models. Maternal age, education, and marital status were identified as potential confounders a priori and variables with \( P < 0.1 \) were included in multivariable models for women in the cross-sectional study. If variables were collinear, variables with the least amount of missing data were included in the multivariable model.

HIV infections detected among pregnant and postpartum women in the cross-sectional and programmatic abstraction only studies (including those detected through testing by study nurses) with a prior HIV-negative test during pregnancy (or those with no documentation of an HIV-negative test during pregnancy) were classified as incident infections. Timing of seroconversion was calculated as the midpoint between the last HIV-negative test during pregnancy and first HIV-positive test. Women who tested HIV-positive during pregnancy or less than 72 hours after delivery were classified as having acquired HIV during pregnancy. If the first HIV-positive test was conducted postpartum but the time of seroconversion based on the midpoint calculation was during pregnancy, infections were classified as acquired during pregnancy. Person-time for women with incident infections was calculated as the time between the first HIV-negative test and first HIV-positive test; person-time was stratified by before and after delivery to compare incidence rates during pregnancy vs. postpartum. A sensitivity analysis of incidence rates excluding postpartum women who lacked documentation of an HIV-negative test during pregnancy was conducted. All statistical analyses were performed using STATA v15.1 (College Station, TX).
RESULTS

Study Population
Overall, 5,894 women were enrolled; 1,882 (32%) during pregnancy, 130 (2%) at labor and delivery, and 3,882 (66%) postpartum (1,700 (44%) at 6 weeks, 512 (13%) at 6 months and 1,670 (43%) at 9 months) (Table 1 and Supplement Figure 1). The median age was 23 years (interquartile range [IQR]: 21–28). The median number of ANC visits was 3 (IQR: 2–4). Among women enrolled at 9 months postpartum, the median number of PNC visits was 6 (IQR 2–8).

Women in the programmatic abstraction only study (n=3,214) were older (median 24, IQR: 21–28 versus median 23, IQR: 20–27; P<.001), had more ANC visits (median 4, IQR: 3–5 versus median 2, IQR: 1–2, P<.001) than women in the cross-sectional study (n=2,770) (Table 2 and Supplement Table 1). The number of PNC visits was higher among women in the programmatic abstraction only study than the cross-sectional study (median 7, IQR: 6–8 versus median 2, IQR: 2–3, P<.001), among women enrolled at 9 months postpartum.

Among 2,770 women enrolled in the cross-sectional study; 928 (34%) enrolled during the third trimester; 129 (5%) at delivery; and 540 (19%) at 6 weeks, 512 (18%) at 6 months, and 661 (24%) at 9 months postpartum (Table 2). The majority (67%) were married, with a median relationship duration of 4 years (IQR: 2–7).

TABLE 1. Characteristics of Participants Enrolled in a Cross-Sectional and Programmatic Abstraction Only Study in Kenya, by Enrollment Visit

|                      | All Women (N=5,894) | ≥28 Weeks’ Gestation (n=1,882) | Delivery/Labor (n=130) | 6 Weeks (n=1,700) | 6 Months (n=512) | 9 Months (n=1,670) |
|----------------------|---------------------|--------------------------------|------------------------|------------------|------------------|-------------------|
| N                    | 5,894               | 1,882                          | 130                    | 1,700            | 512              | 1,670             |
| No. (%)              | 23 (21–28)          | 1,881                          | 23 (21–28)             | 1,697            | 23 (20–27)       | 1,669             |
| Age, median (IQR), years | 23 (21–28)          | 1,881                          | 23 (21–28)             | 1,697            | 23 (20–27)       | 1,669             |
| Age range, years     |                     |                                |                        |                  |                  |                   |
| <21                  | 1,456 (25)          | 456 (24)                       | 42 (33)                | 431 (25)         | 149 (29)         | 379 (23)          |
| 21–30                | 3,705 (63)          | 1,188 (63)                     | 76 (59)                | 1,048 (62)       | 321 (63)         | 1,072 (64)        |
| ≥30                  | 728 (12)            | 237 (13)                       | 12 (9)                 | 218 (13)         | 42 (8)           | 219 (13)          |
| Enrollment site      |                     |                                |                        |                  |                  |                   |
| Ahero                | 2,039 (35)          | 663 (35)                       | 75 (58)                | 491 (29)         | 292 (57)         | 518 (31)          |
| Bondo                | 2,226 (38)          | 730 (39)                       | 54 (42)                | 657 (39)         | 219 (43)         | 566 (34)          |
| Riruta               | 503 (9)             | 50 (3)                         | —                      | 181 (11)         | 1 (<1)           | 271 (16)          |
| Siaya                | 519 (9)             | 178 (9)                        | 1 (1)                  | 162 (10)         | —                | 178 (11)          |
| Rachuonyo            | 607 (10)            | 261 (14)                       | —                      | 209 (12)         | —                | 137 (8)           |
| Enrollment yeara     | 5,894               | 1,882                          | 130                    | 1,700            | 512              | 1,670             |
| 2017                 | 1,226 (21)          | 391 (21)                       | 48 (37)                | 253 (15)         | 299 (58)         | 235 (14)          |
| 2018                 | 1,237 (21)          | 537 (29)                       | 81 (63)                | 220 (13)         | 212 (41)         | 187 (11)          |
| 2019                 | 3,431 (58)          | 954 (51)                       | 1 (1)                  | 1,227 (72)       | 1 (<1)           | 1,248 (75)        |
| ANC visits documented, median (IQR)b | 5,854 | 1 (2–4)          | 1,842                  | 3 (2–4)          | 130              | 1,700             |
| PNC visits documented median (IQR)c | 3,882 | 3 (1–5)          | 2 (1–5)                | 1,700             | 3 (1–2)          | 512            |
| HIV retests, median (IQR)d | 5,894 | 1 (0–2)          | 1,882                  | 0 (0–1)          | 130              | 1,700             |
| Incident HIV-infections | 5,894 | 18 (<1)          | 1,882                  | 8 (<1)           | 130              | 1,700             |

Abbreviations: ANC, antenatal care; IQR, interquartile range; PNC, postnatal care.

a All women enrolled in the years 2017 and 2018 were thorough cross-sectional study only.

b As per maternal and child health booklet documentation. One woman who presented for care at 6 weeks postpartum who was HIV-positive was identified as having an incident infection detected through delivery testing during study screening.

c Among women enrolled at postpartum.

d Including all HIV tests during most recent pregnancy and postpartum, excluding test done as part of study.
## TABLE 2. Characteristics of Participants Enrolled in a Cross-Sectional Study in Kenya, by Enrollment Visit

| Demographic characteristics | CROSS-SECTIONAL STUDY (N=2,770) |
|-----------------------------|---------------------------------|
|                             | All Women (N=2,770)             | ≥28 Weeks’ Gestation (n=928) | Delivery/Labor (n=129) | 6 Weeks (n=540) | 6 Months (n=512) | 9 Months (n=661) |
|                             | n | No. (%) | n | No. (%) | n | No. (%) | n | No. (%) | n | No. (%) | n | No. (%) |
| Completed secondary education | 2,769 | 1442 (52) | 928 | 530 (57) | 129 | 53 (41) | 540 | 265 (49) | 511 | 243 (48) | 661 | 351 (53) |
| Completed education (years) median (IQR) | 2,766 | 12 (8–13) | 926 | 12 (8–14) | 129 | 10 (8–12) | 539 | 12 (8–12) | 511 | 11 (8–12) | 661 | 12 (8–13) |
| Neither parent alive | 2,768 | 357 (13) | 926 | 116 (13) | 129 | 13 (10) | 540 | 60 (11) | 512 | 78 (15) | 661 | 90 (14) |
| Monthly household income ≥10,000 KSH | 1,767 | 695 (39) | 596 | 246 (41) | 80 | 40 (50) | 357 | 133 (37) | 345 | 98 (28) | 389 | 178 (46) |

### Relationship characteristics and sexual behavior

|                             | CROSS-SECTIONAL STUDY (N=2,770) |
|-----------------------------|---------------------------------|
|                             | All Women (N=2,770)             | ≥28 Weeks’ Gestation (n=928) | Delivery/Labor (n=129) | 6 Weeks (n=540) | 6 Months (n=512) | 9 Months (n=661) |
|                             | n | No. (%) | n | No. (%) | n | No. (%) | n | No. (%) | n | No. (%) | n | No. (%) |
| Married | 2,729 | 1839 (67) | 917 | 665 (73) | 127 | 77 (61) | 532 | 325 (61) | 504 | 340 (67) | 649 | 432 (67) |
| Currently in a relationship | 2,761 | 1981 (72) | 926 | 705 (76) | 129 | 81 (63) | 539 | 355 (66) | 507 | 364 (72) | 660 | 476 (72) |
| Relationship duration, median (IQR), years | 1,974 | 4 (2–7) | 701 | 4 (2–7) | 81 | 4 (2–8) | 354 | 3 (2–7) | 362 | 4 (2–6) | 476 | 4 (2–7) |
| Polygamous marriage | 1,956 | 141 (7) | 696 | 43 (6) | 79 | 8 (10) | 351 | 33 (9) | 360 | 30 (8) | 470 | 27 (6) |
| Frequency of sex (last month), median (IQR) | 2,438 | 0 (0–2) | 794 | 0 (0–2) | 125 | 0 (0) | 513 | 0 (0) | 449 | 1 (0–4) | 557 | 2 (0–5) |
| Any condomless sex (last month) | 968 | 862 (89) | 289 | 262 (91) | 80 | 40 (50) | 357 | 133 (37) | 345 | 98 (28) | 389 | 178 (46) |
| Age at sexual debut, median (IQR), years | 2,485 | 16 (15–18) | 821 | 16 (15–18) | 110 | 15 (14–18) | 489 | 15 (15–18) | 477 | 16 (15–18) | 588 | 16 (15–18) |
| Lifetime number of sexual partners, median (IQR) | 2,770 | 2 (1–3) | 928 | 2 (1–3) | 129 | 2 (1–3) | 540 | 2 (1–3) | 512 | 2 (1–3) | 661 | 2 (1–3) |
| Partner completed secondary education | 1,935 | 1366 (71) | 685 | 500 (73) | 78 | 49 (63) | 350 | 245 (71) | 359 | 251 (70) | 463 | 326 (70) |
| Partner age difference, median (IQR), years older | 1,857 | 5 (3–7) | 671 | 5 (3–7) | 70 | 5 (4–7) | 328 | 5 (3–7) | 340 | 5 (4–8) | 448 | 5 (3–7) |
| Partner circumcised | 1,918 | 1338 (70) | 684 | 465 (68) | 77 | 55 (71) | 345 | 245 (71) | 351 | 251 (71) | 461 | 322 (70) |
| Discussed HIV test with partner prior to test | 1,972 | 1274 (65) | 703 | 448 (64) | 80 | 54 (66) | 355 | 234 (66) | 361 | 241 (67) | 473 | 297 (63) |
| Partner HIV status | 1,981 | 705 | 81 | 355 | 364 | 476 |
| Negative | 1309 | 446 (63) | 51 | 63 | 228 | 64 | 259 | 71 | 325 | 68 |
| Positive | 15 | 7 (1) | 0 | 0 | 1 (1) |
| Unknown | 657 | 252 (36) | 30 | 37 | 127 (36) | 104 (29) | 144 (30) |
| Partner currently on ART | 15 | 12 (80) | 7 | 4 (57) | 0 | 0 | 0 | 1 | 1 (100) | 7 | 100 |

### Reproductive history and clinical history

|                             | CROSS-SECTIONAL STUDY (N=2,770) |
|-----------------------------|---------------------------------|
|                             | All Women (N=2,770)             | ≥28 Weeks’ Gestation (n=928) | Delivery/Labor (n=129) | 6 Weeks (n=540) | 6 Months (n=512) | 9 Months (n=661) |
|                             | n | No. (%) | n | No. (%) | n | No. (%) | n | No. (%) | n | No. (%) | n | No. (%) |
| Reproductive history and clinical history | Gravity, median (IQR) | 2,770 | 1 (1–2) | 928 | 1 (1–2) | 129 | 2 (1–3) | 540 | 1 (1–2) | 512 | 1 (1–2) | 661 | 1 (1–2) |
|                                      | Number of living children, median (IQR) | 1,337 | 2 (1–3) | 462 | 1 (1–2) | 66 | 2 (2–3) | 246 | 2 (2–3) | 244 | 2 (2–3) | 319 | 2 (2–3) |
|                                      | Facility delivery, median (IQR) | 1,177 | 1096 (93) | 335 | 303 (90) | 58 | 56 (97) | 239 | 225 (94) | 235 | 216 (91) | 310 | 296 (95) |
|                                      | Ever diagnosed with STI, median (IQR) | 2,759 | 31 (1) | 926 | 12 (1) | 128 | 1 (1) | 539 | 4 (1) | 512 | 9 (2) | 654 | 5 (1) |
|                                      | Ever heard of PrEP | 1,346 | 892 (66) | 477 | 343 (72) | 41 | 24 (59) | 251 | 161 (64) | 182 | 117 (64) | 395 | 247 (63) |
|                                      | Ever used PrEP, median (IQR) | 892 | 72 (8) | 343 | 27 (8) | 24 | 2 (8) | 161 | 16 (10) | 117 | 8 (7) | 247 | 19 (8) |
|                                      | Incident HIV infections | 2,770 | 9 (1<1) | 928 | 5 (1) | 0 | 0 | 0 | 0 | 0 | 0 |

**Abbreviations:** IQR, interquartile range; ART, antiretroviral therapy; PrEP, pre-exposure prophylaxis; STI, sexually transmitted infection.

---

Among women with current partners.

* Among women with current partners with HIV.

* Among women with previous pregnancies.

* Among multiparous women including postpartum women who delivered.

* Self-reported history of STI and rapid plasma reagin test.

* Among women who heard of PrEP.
Among 968 women who reported on sexual activity, 89% reported condomless sex the month before enrollment. Overall, 31 (1%) women reported a history of sexually transmitted infections. Most (67%) women with partners said their partner was tested for HIV, 1% (n=15) reported their partners were HIV-positive and 66% (n=1,309) reported their partners were HIV-negative.

**Prevalence of Programmatic Retesting**

Among 4,926 women enrolled in either the cross-sectional study or the programmatic abstraction only study, 77% received at least 1 programmatic retest. Only 3% (n=199) did not have documentation of a prior HIV test in pregnancy (n=1 enrolled at delivery, n=22 at 6 weeks, n=61 at 6 months, and n=115 at 9 months postpartum). Among women who lacked documentation of initial testing, 16 women missed multiple opportunities for HIV testing and were tested for the first time during delivery (n=1) or postpartum (n=11 at 6 weeks, n=1 at 6 months, and n=3 at 9 months). Prevalence of programmatic retesting was higher (65%) at 6 weeks and (72%) at 9 months postpartum, than in pregnancy (32%), at delivery (23%), and at 6 months postpartum (28%) (P<.001 for all comparisons). Prevalence of programmatic retesting was similar at all time points by study protocol, except for more frequent retesting during pregnancy in the cross-sectional study than the programmatic abstraction only study (38% versus 33%, respectively; P=.01). The frequency of programmatic retesting at specific time points increased significantly between 2016 and 2019 during pregnancy (27% to 42%), at delivery (4% to 35%), and 6 weeks postpartum (53% to 64%); no differences in the frequency of retesting were detected at 6 months postpartum. Retesting was significantly higher in 2019 than 2018 (72% versus 31%; P<.001) (Figure 1) and differed by site across all years (Figure 2; P<.0001).

We examined completeness of retesting according to Kenyan guidelines among 2,289 women enrolled in the programmatic abstraction only study, with documented visit dates. Overall, 44% of 2,289 women were retested in the third trimester, which increased to 51% when restricted to women enrolled at or after delivery (n=2,128). Coverage of retesting was higher during the postpartum period: 68% of 2,135 women with a PNC visit at 6 weeks retested and 86% of 1,004 women with a PNC visit at either 6 or 9 months retested. However, only 22% of 1,004 women were retested as per Kenyan guidelines (Supplement Figure 2).

Among 1,009 women enrolled at 9 months postpartum, 271 (27%) received a retest during pregnancy, 980 (97%) received a retest postpartum, and 261 (26%) received retests both in pregnancy and postpartum.

**Cofactors of Programmatic Retesting**

Among 661 women enrolled in the cross-sectional study at 9 months postpartum, 566 (86%) received at least 1 HIV retest: 218 (39%) received 1; 227 (40%) received 2; 97 (17%) received 3; 20 (4%) received 4; and 4 (1%) received 5 retests. While retesting was more common among married than unmarried women (68% versus 32%, respectively; P=.01) and women who had more prior pregnancies and less likely among women with a partner who completed secondary education, these associations were not significant in the multivariable model (Supplement Table 2). Being married (P=.01), having more previous pregnancies (P<.001), and enrolling in 2018 (versus 2017), were associated with retesting at least twice (P<.001), while having a partner with unknown or HIV-positive status was associated with a 26% decrease in likelihood of receiving at least 2 retests (P<.001) (Table 3). In the adjusted model, only enrollment year remained significant.

Overall, 990 (98%) of 1,009 women enrolled in the programmatic abstraction only study received at least 1 retest, 870 (86%) received at least 2 retests, and 19 (2%) were not retested. Maternal age, number of ANC visits, and number of PNC visits were not associated with receiving at least 1 retest. In an exploratory analysis, women aged 21–30 years were less likely to receive at least 2 retests (prevalence ratio: 0.96, 95% CI=0.94, 0.99; P<.01) than younger women, while women who had ≥2 PNC visits (prevalence ratio: 1.17, 95% CI=1.02, 1.34; P=.03) were more likely to receive at least 2 retests in a univariate model (Supplement Tables 3 and 4).

**HIV Incidence**

Among 5,878 women, we identified 18 (0.3%) with incident maternal HIV infections who were previously HIV-negative: 9 (0.4%) of 2,011 during the third trimester/delivery; and 9 (0.2%) of 3,867 during the postpartum (Table 1) (6 [0.4%] of 1,689 at 6 weeks, 1 [0.2%] of 511 at 6 months, and 2 [0.1%] of 1,667 at 9 months postpartum). After 3,627 person-years of follow-up, the overall incidence rate during pregnancy and postpartum was 0.50/100 PY (95% CI=0.31, 0.79); incidence in pregnancy was 0.72/100 PY; (95% CI=0.43, 0.99).
1.22), significantly higher than in postpartum (0.23/100 PY; 95% CI=0.09, 0.62; incidence rate ratio (IRR): 3.09; 95% CI=0.97, 12.90, \( P = .02 \)). The overall incidence rate was similar after excluding women with no documented prior negative HIV test during pregnancy. Incidence rates were similar in the cross-sectional and programmatic abstraction only studies (IRR: 1.13; 95% CI=0.40, 3.21, \( P = 0.4 \)). All women with incident infections received an initial HIV test during ANC or PNC before testing positive, with the following distribution at the last negative HIV test; 15 (83%) during pregnancy, 1 (6%) at delivery, 1 (6%) at 6 weeks and 1 (6%) at 6 months postpartum.

**DISCUSSION**

Despite guidelines to conduct maternal HIV retesting during pregnancy, during labor/delivery, and postpartum, we found HIV retesting was inconsistently conducted in Kenyan PMTCT programs. We found 77% of women were retested during pregnancy or postpartum. A higher proportion of women were retested during pregnancy (32%) than previously reported in other studies conducted in Zambia (25%) and Kenya (10%) but lower (62%) than a recent study in South Africa. Few (3%) women had no documentation of HIV testing in pregnancy. Among women with retesting data available through 9 months postpartum, we found retesting was more consistently implemented postpartum: 97% were retested postpartum (26% in both pregnancy and postpartum). Retesting was highest at 6 weeks (65%) and 9 months postpartum (72%). The relatively higher frequency of retesting at 6 weeks postpartum may be due to higher attendance for infant immunizations, prioritization of retesting for HIV by health care providers, provider perceptions of HIV risk during the peripartum period, and/or “catch-up” retesting if retesting in pregnancy and labor/delivery was missed.

Retesting during pregnancy was higher in our study (32%) than in the other study also conducted in Kenya (10%), differences which may be explained by changes in guidelines and gradual roll-out of retesting services. Guidelines for
maternal HIV retesting have changed over time both nationally and globally, with initial recommendations to conduct retesting during pregnancy, and modifications to recommendations to test multiple times during pregnancy and while breastfeeding.9,10,16 Our study was conducted at a time when scale-up of retesting during pregnancy may have occurred in Kenya, and we did detect an increased frequency of retesting over time, consistent with a study in South Africa.14

To determine whether specific groups of women are more likely to be retested, we examined individual- and facility-level correlates of retesting. We found the frequency of retesting was higher among married women, results that are consistent with a prior study in Kenya.19 While unmarried women attended fewer ANC visits than married women, the number of ANC visits was not associated with receiving a retest in our study, in contrast to a study conducted in Tanzania.15 Women who had several opportunities to be retested in the postpartum were more likely to be retested at least twice in our study. We also found differences in retesting between sites that may be attributed to differences in availability of test kits, clinic volume, or differences in prioritization for retesting by providers by site.

Efforts to improve coverage of retesting will continue to be relevant for EMTCT as the contribution of incident maternal HIV infections to MTCT is expected to increase with successful scale-up of PMTCT interventions for women with chronic HIV infection. Compared to the pre-ART era, risk of MTCT among women with incident versus chronic HIV infections is up to 9-fold higher.4 However, effectiveness of retesting for PMTCT will vary based on timing of testing, sexual behavior of peripartum women, and HIV incidence. Recent modeling studies in Kenya suggest that maternal retesting is cost-effective when retesting occurs in late pregnancy with catch-up testing at delivery or 6 weeks postpartum for women without antenatal retesting; however, retesting at 2 or more time points had limited utility and was not cost-effective.20

In our study, HIV incidence during pregnancy and postpartum was 0.50/100 PY, which was lower than other recent studies of HIV incidence in Kenya and other parts of sub-Saharan Africa,2,21–24 and may reflect declines in HIV incidence in Kenya. As scale-up of implementation

Abbreviation: PP, postpartum.

9 All women enrolled in the cross-sectional and programmatic abstraction only studies at all sites; retesting conducted as part of the cross-sectional study procedures was omitted.

10 The proportion of women retested at each time point was calculated at visits when they enrolled and at all prior time points and retesting conducted as part of the cross-sectional study procedures was omitted; therefore, women can be included in multiple time points.

14 P < .001.

FIGURE 2. Prevalence of Programmatic Maternal HIV Retesting During Pregnancy and Postpartum in 5 Health Facilities in Kenya by Health Facility.
and frequency of retesting increases, the number of incident maternal HIV infections detected at later time points along the pregnancy-postpartum continuum may decline as women who acquire HIV earlier are identified. Incidence in our study was 3-fold higher during pregnancy than postpartum, which differs from a study noting an increased risk of HIV acquisition per condomless sex act postpartum than during pregnancy and suggests fewer infections were acquired postpartum in our study. As maternal HIV incidence declines with the implementation of HIV prevention interventions, such as preexposure prophylaxis (PrEP), retesting may become less effective for PMTCT. In a recent, large implementation project in Kenya, more than 20% of HIV-negative pregnant and postpartum women-initiated PrEP, and there were no incident HIV infections among women who used PrEP. Yet, incident infections were captured in our study in which PrEP was available at clinics and 8% of women reported using PrEP. These results suggest that either higher uptake of PrEP, or more concentrated PrEP use among higher-risk women, will be necessary to reduce the impact of maternal retesting on PMTCT.

### TABLE 3. Correlates of Participants Receiving At Least 2 HIV Retests by 9 Months Postpartum (N=661), Cross-Sectional Study Only, Kenya

| Received at Least 2 HIV Retests | N | No (N=313) | Yes (N=348) | Crude PR[^b] (95% CI) | P Value | Adjusted PR[^b] (95% CI) | P Value |
|-------------------------------|---|------------|-------------|-----------------------|---------|-------------------------|---------|
| **Sociodemographic characteristics** | | | | | | | |
| Age range, years | 313 | 348 | | | | | |
| <21 | 77 (25) | 86 (25) | Ref | | | | |
| 21–30 | 199 (64) | 220 (63) | 1.00 (0.85, 1.16) | 1.0 | | | |
| >30 | 37 (12) | 42 (12) | 1.01 (0.73, 1.39) | 1.0 | | | |
| Enrollment year | 313 | 348 | | | | | |
| 2017 | 117 (35) | 118 (34) | Ref | Ref | | | |
| 2018 | 86 (27) | 101 (29) | 1.08 (1.07, 1.08) | <.001 | 1.07 (1.05, 1.10) | <.001 | |
| 2019 | 110 (27) | 129 (37) | 1.07 (0.60, 1.93) | .8 | 1.08 (0.62, 1.89) | .8 | |
| Completed secondary education | 313 | 348 | 172 (49) | 0.86 (0.74, 1.00) | .06 | 0.86 (0.75, 1.00) | .05 | |
| Neither parent alive | 313 | 348 | 54 (16) | 1.17 (0.92, 1.47) | .2 | | | |
| Monthly household income ≥10,000KSH | 190 | 199 | 88 (44) | 0.94 (0.72, 1.22) | .6 | | | |
| **Relationship characteristics and sexual behavior** | | | | | | | |
| Married | 308 | 341 | 245 (72) | 1.28 (1.19, 1.38) | <.001 | | | |
| Polygamous marriage[^d] | 204 | 266 | 18 (7) | 1.19 (0.92, 1.55) | .2 | | | |
| Partner completed secondary education[^d] | 197 | 266 | 179 (67) | 0.86 (0.72, 1.04) | .1 | | | |
| Partner HIV status unknown/positive[^d] | 206 | 270 | 76 (28) | 0.84 (0.79, 0.89) | <.001 | | | |
| Frequency of condomless sex (last month) | 145 | 160 | 140 (88) | 0.88 (0.63, 1.23) | .5 | | | |
| Lifetime number of sexual partners | 313 | 348 | 113 (32) | 1.02 (0.88, 1.19) | .7 | | | |
| **Reproductive history** | | | | | | | |
| Gravidity, mean (95% CI) | 313 | 348 | 2.03 (1.89, 2.18) | 1.08 (1.02, 1.14) | .01 | | | |
| Facility delivery[^e] | 135 | 175 | 166 (95) | 0.87 (0.59, 1.29) | .5 | | | |

**Abbreviations:** PR, prevalence ratio; CI, confidence interval.
[^b]: Due to collinearity, variables maternal age, marital status, partner HIV status and gravidity were excluded from the multivariate analysis. Variables identified as potential confounders a priori were included in multivariate Poisson GLMs; maternal age, education except marital status.
[^d]: Using robust standard errors.
[^e]: Statistically significant.
[^f]: Among women with current partner.
[^g]: Among multiparous women.
One approach to overcome both individual- and facility-level barriers to maternal retesting is HIV self-testing. HIV self-testing decreases provider time associated with routine testing; in busy MCH clinics, this is particularly appealing. Women who have previously received counseling on HIV testing and MTCT may be comfortable with the testing process and prefer a test that uses saliva rather than blood samples. A study in Kenya that offered women the choice of an oral HIV self-test or a routine HIV blood test with a provider found over half of women preferred the oral HIV self-test and cited privacy, ease of use, and less time for testing as reasons for this preference.27 Home-based oral HIV self-testing has an additional benefit in that it can be used as a secondary distribution strategy to have male partners tested, and has previously been shown to be highly acceptable to women receiving ANC and postnatal/infant care in sub-Saharan Africa.28–31 While rapid HIV tests that use oral fluid have lower sensitivity than those that use blood samples,32 WHO recommends HIV self-testing (including with oral fluid) as a convenient and confidential additional approach for testing, coupled with confirmatory testing with a provider if results are reactive.33 Alternative approaches to improve retesting coverage should be tailored to local context and settings but could include maintaining supply chains of test kits to avoid stock-outs and eliminate the need to prioritize recipients of retesting, educating providers to reiterate the need and rationale for retesting, and/or task-shifting to provide sufficient staff time to conduct retesting.

Our study had several strengths. We abstracted information on maternal HIV retesting during pregnancy, delivery, and throughout the postpartum period from a large number of women to comprehensively assess programmatic retesting. We captured variation in maternal retesting in different sites and over time. We estimated HIV incidence during pregnancy and postpartum and characterized the time points when infections were detected by retesting.

Limitations

Our study is also subject to some limitations. Our findings may not be generalizable to settings where HIV prevalence is lower or where guidelines for retesting differ. We also did not capture community-, facility- or provider-related factors that may have impacted retesting such as PrEP coverage in the community or clinic, provider skills and trainings, or stock-outs of test kits. In addition, data abstracted from MCH booklets may be incomplete and underreport ANC/PNC visits and HIV testing. Finally, we had limited statistical power to compare incidence rates between pregnancy and postpartum.

CONCLUSION

In conclusion, maternal HIV retesting is inconsistently implemented in Kenya but has increased over time. Overall, maternal HIV incidence was lower in our study compared to recent studies in other parts of sub-Saharan Africa. Measuring service delivery gaps in offering maternal HIV retesting and impact of retesting programs to detect and treat new maternal HIV infections should be prioritized to monitor progress toward EMTCT.

Acknowledgments: We would like to acknowledge the support from University of Washington’s Center for Studies in Demography and Ecology (NIH/NICHD F2C HD042628). We would also like to acknowledge the significant contributions from study participants.

Funding: This study was funded by National Institutes of Health (NIH) and National Institute of Allergy and Infectious Diseases (NIAID) NIH/ NIAID K01 AI116298 (ALD) and with research infrastructure support from NIH/NIAID F30 AI027797, and Global Center for Integrated Health of Women, Adolescents, and Children. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the funding agencies.

Author contributions: ALD, DM, and JK designed the study. MP and ALD contributed to the literature search. JN, SF, PK, DM and ALD contributed to collecting data. MP and ALD were responsible for conducting analysis. All authors have provided substantial input to the document.

Competing interests: None declared.

REFERENCES

1. Global HIV & AIDS statistics — 2020 fact sheet. UNAIDS. Accessed January 20, 2022. https://www.unaids.org/en/resources/fact-sheet

2. Graybill LA, Kasaro M, Freeborn K, et al. Incident HIV among pregnant and breastfeeding women in sub-Saharan Africa: a systematic review and meta-analysis. AIDS. 2020;34(9):761–776. CrossRef Medline

3. Johnson LF, Stimson K, Newell ML, et al. The contribution of maternal HIV seroconversion during late pregnancy and breastfeeding to mother-to-child transmission of HIV. J Acquir Immune Defic Syndr. 2012;59(4):417–425. CrossRef Medline

4. Drake AL, Wagner A, Richardson B, John-Stewart G. Incident HIV during pregnancy and postpartum and risk of mother-to-child HIV transmission: a systematic review and meta-analysis. PLoS Med. 2014;11(2):e1001608. CrossRef Medline

5. Humphrey JH, Marinda E, Mutasa K, et al. Mother to child transmission of HIV among Zimbabwean women who seroconverted postnata- tally: prospective cohort study. BMJ. 2010;341(dec22 1):c6580. CrossRef Medline

6. Liang K, Gui X, Zhang Y, Zhuang K, Meyers K, Ho DD. A case series of 104 women infected with HIV-1 via blood transfusion postnatally; high rate of HIV-1 transmission to infants through breastfeeding. J Infect Dis. 2009;200(5):682–686. CrossRef Medline

7. Van de Perre P, Simonon A, Maelard P, et al. Postnatal transmission of human immunodeficiency virus type 1 from mother to infant. A prospective cohort study in Kigali, Rwanda. N Engl J Med. 1991;325(9):593–598. CrossRef Medline
8. World Health Organization (WHO). Guidance on Global Scale-up of the Prevention of Mother-to-Child Transmission of HIV: Towards Universal Access for Women, Infants and Young Children and Eliminating HIV and AIDS among Children. WHO; 2007. Accessed January 20, 2022. https://apps.who.int/iris/handle/10665/43728

9. World Health Organization (WHO). Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants: Towards Universal Access: Recommendations for a Public Health Approach. WHO; 2006. Accessed January 20, 2022. https://www.who.int/hiv/pub/guidelines/ptmtl/en/

10. World Health Organization (WHO). Consolidated Guidelines on HIV Testing Services: SCs: Consent, Confidentiality, Counselling. Correct Results and Connection 2015. WHO; 2015. Accessed January 20, 2022. https://www.ncbi.nlm.nih.gov/books/NBK316021

11. Republic of Kenya. Ministry of Health. National AIDS & STI Control Program (NASCOP). Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV Infection in Kenya. NASCOP; 2018. Accessed January 20, 2022. http://cquin.icap.columbia.edu/wp-content/uploads/2017/04/ICAP_CQUIN_Kenya-ARV-Guidelines-2018-Final_20thAug2018.pdf

12. Mandola J, Kasonde P, Badru T, Dirks R, Torpey K. HIV Retesting of HIV-negative pregnant women in the context of prevention of mother-to-child transmission of HIV in primary health centers in rural Zambia: what did we learn? J Int Assoc Provid AIDS Care. 2019;18. CrossRef. Medline

13. Heemelaar S, Habets N, Makukula Z, van Roosmalen J, van den Ende C. HIV Retesting of HIV-positive women in rural Zambia: a qualitative study. J Int AIDS Soc. 2015;20(3):277–283. CrossRef. Medline

14. de Beer S, Kalk E, Kroon M, et al. A longitudinal analysis of the completeness of maternal testing, including repeat testing in Cape Town, South Africa. J Int AIDS Soc. 2020;23(1):e25441. CrossRef. Medline

15. Nungu SI, Mgamba JM, Runisha SF, Semali IA. Uptake and determinants for HIV postpartum re-testing among mothers with prenatal negative status in Njombe region, Tanzania. BMC Infect Dis. 2019;19(1):398. CrossRef. Medline

16. Drake AL, Thomson KA, Quinn C, et al. Retest and treat: a review of national HIV retesting guidelines to inform elimination of mother-to-child HIV transmission (EMTCT) efforts. J Int AIDS Soc. 2019;22(4):e25271. CrossRef. Medline

17. Breslow NE. Generalized Linear Models: Checking Assumptions and Strengthening Conclusions. University of Washington, Department of Statistics, 1996. 1996. Accessed January 20, 2022. https://sites.eecs.ist.psu.edu/viewdoc/download?doi=10.1.1.50.6105&rep=rep1&type=pdf

18. Lee J, Chia KS. Estimation of prevalence rate ratios for cross sectional data: an example in occupational epidemiology. Occup Environ Med. 1993;50(9):861–862. CrossRef. Medline

19. Rogers AJ, Akama E, Welke E, et al. Implementation of repeat HIV testing during pregnancy in southwestern Kenya: progress and missed opportunities. J Int AIDS Soc. 2017;20(4):e25036. CrossRef. Medline

20. Meisner J, Roberts DA, Rodriguez P, et al. Optimizing HIV retesting during pregnancy and postpartum in four countries: a cost-effectiveness analysis. J Int AIDS Soc. 2021;24(4):e25686. CrossRef. Medline

21. Moodley D, Esterhuizen TM, Patther T, Chetty V, Ngaleka L. High HIV incidence during pregnancy: compelling reason for repeat HIV testing. AIDS. 2009;23(10):1255–1259. CrossRef. Medline

22. Rehle T, Shisana O, Pillay V, Zuma K, Puren A, Parker W. National HIV incidence measures—new insights into the South African epidemic. S Afr Med J. 2007;97(3):194–199. Medline

23. Urasa W, Kaaya S, Mwagale F, et al. Evidence of a substantial decline in prevalence of HIV-1 infection among pregnant women: data from 1995 to 2003 in Dar es Salaam, Tanzania. Scand J Public Health. 2006;34(3):272–278. https://www.jstor.org/stable/45149743. Medline

24. Machekano R, Tiam A, Kassaye S, et al. HIV incidence among pregnant and postpartum women in a high prevalence setting. PLoS One. 2018;13(12):e0209782. CrossRef. Medline

25. Thomson KA, Hughes J, Baeten JM, et al. Increased risk of HIV acquisition among women throughout pregnancy and during the postpartum period: a prospective per-coital act analysis among women with HIV-infected partners. J Inf Dis. 2018;218(1):16–25. CrossRef. Medline

26. Kinuthia J, Pintye J, Alaba F, et al; PreP Implementation for Young Women and Adolescents (PrIYA) programme. Pre-exposure prophylaxis uptake and early continuation among pregnant and postpartum women within maternal and child health clinics in Kenya: results from an implementation programme. Lancet HIV. 2020;7(1):e38–e48. CrossRef. Medline

27. Oyaro P, Kwenza Z, Bukusi EA, Baeten JM. Is HIV self-testing a strategy to increase repeat testing among pregnant and postpartum women? A pilot mixed methods study. J Acquir Immune Defic Syndr. 1999;20(4):365–371. CrossRef. Medline

28. Masters SH, Agot K, Olanyo B, Napierala Mavedzenge S, Maman S, Thirumurthy H. Promoting partner testing and couples testing through secondary distribution of HIV self-tests: a randomized clinical trial. PLoS Med. 2016;13(11):e1002166. CrossRef. Medline

29. Pintye J, Drake AL, Begnel E, et al. Acceptability and outcomes of distributing HIV self-tests for male partner testing in Kenyan maternal and child health and family planning clinics. AIDS. 2019;33(8):1369–1378. CrossRef. Medline

30. Gichangi A, Wambua J, Mutwiiwa S, et al. Impact of HIV self-test distribution to male partners of ANC clients: results of a randomized controlled trial in Kenya. J Acquir Immune Defic Syndr. 2018;79(4):467–473. CrossRef. Medline

31. Hershov RB, Zimba CC, Mwewa O, et al. Perspectives on HIV partner notification, partner HIV self-testing and partner home-based HIV testing by pregnant and postpartum women in antenatal settings: a qualitative analysis in Malawi and Zambia. J Int AIDS Soc. 2019;22 Suppl 3(Suppl 3):e25293. CrossRef. Medline

32. Pavie J, Rachline A, Loze B, et al. Sensitivity of five rapid HIV tests on oral fluid or finger-stick whole blood: a real-time comparison in a healthcare setting. J Acquir Immune Defic Syndr. 2019;7(1):e1–e4. CrossRef. Medline

33. World Health Organization (WHO). Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach. WHO; 2021. Accessed January 20, 2022. https://www.who.int/publications-detail-redirect/9789240031593